Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 03 2019
Historique:
received: 23 07 2018
revised: 20 09 2018
accepted: 28 11 2018
pubmed: 6 12 2018
medline: 9 4 2020
entrez: 6 12 2018
Statut: ppublish

Résumé

We have assessed the combination of DC-CIK with S-1 plus cisplatin chemotherapy in advanced gastric cancer (AGC) and the role of mutational analysis of circulating tumor DNA (ctDNA) and T-cell receptor (TCR) repertoire in predicting clinical outcomes. Consecutive patients ( The DC-CIK infusions were well tolerated with no serious adverse events. The disease control rates (CR DC-CIK combined with S-1 plus cisplatin provided a favorable PFS and OS in patients with AGC and the combination therapy was safe with tolerable toxicities. Clinical efficacy correlated with decreases in ctDNA mutational profiles and restored TCR repertoire.

Identifiants

pubmed: 30514775
pii: 1078-0432.CCR-18-2360
doi: 10.1158/1078-0432.CCR-18-2360
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
Biomarkers 0
Drug Combinations 0
S 1 (combination) 150863-82-4
Tegafur 1548R74NSZ
Oxonic Acid 5VT6420TIG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1494-1504

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Guoliang Qiao (G)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Xiaoli Wang (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Lei Zhou (L)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Xinna Zhou (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Yuguang Song (Y)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Shuo Wang (S)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Lei Zhao (L)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Michael A Morse (MA)

Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Department of Surgery, Duke University Medical Center, Durham, North Carolina.

Amy Hobeika (A)

Department of Surgery, Duke University Medical Center, Durham, North Carolina.

Jin Song (J)

Geneplus-Beijing Institute, Beijing, China.

Xin Yi (X)

Geneplus-Beijing Institute, Beijing, China.

Xuefeng Xia (X)

Geneplus-Beijing Institute, Beijing, China.

Jun Ren (J)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. jun.ren@duke.edu kim.lyerly@duke.edu.
Department of Surgery, Duke University Medical Center, Durham, North Carolina.

Herbert Kim Lyerly (HK)

Department of Surgery, Duke University Medical Center, Durham, North Carolina. jun.ren@duke.edu kim.lyerly@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH